Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence ofde novoor acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor

AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies

(2012) Cynthie Wong et al.   BREAST CANCER RESEARCH AND TREATMENT

The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer

(2012) Rabia A. Gilani et al.   BREAST CANCER RESEARCH AND TREATMENT

Highly sensitive profiling of CD44+/CD24− breast cancer stem cells by combining global mRNA amplification and next generation sequencing: Evidence for a hyperactive PI3K pathway

(2012) Olaf Hardt et al.   CANCER LETTERS

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

(2012) Andrea Cavazzoni et al.   CANCER LETTERS

Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

(2012) T. Sangai et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1

(2011) J. McBryan et al.   CANCER RESEARCH

Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice

(2011) M. E. Balasis et al.   CLINICAL CANCER RESEARCH

Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment

(2011) A. Nicolini et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors

(2011) Muriel Le Romancer et al.   ENDOCRINE REVIEWS

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance

(2010) Gauri Sabnis et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

(2010) Aurélie Thollet et al.   Molecular Cancer

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Biological reprogramming in acquired resistance to endocrine therapy of breast cancer

(2010) H Aguilar et al.   ONCOGENE

Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen

(2009) Gauri Sabnis et al.   CANCER RESEARCH

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

(2009) Sandra E. Ghayad et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor

(2009) K. R. Coser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The importance of distant metastases in hormone-sensitive breast cancer

(2008) Hope S. Rugo   BREAST

Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprived Cells Reveals a Role for Estrogen Receptor

(2008) S. Masri et al.   CANCER RESEARCH

Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft Model

(2008) L. F. Macedo et al.   CANCER RESEARCH

The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop

(2008) X. Wang et al.   CANCER RESEARCH

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer

(2008) Sandra E Ghayad et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute